ClinicalTrials.gg
RecruitingNCT07662148Updated Jul 27, 2026

A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo

A Phase 1 interventional study of BIIB144 and Placebo in Healthy Volunteer, sponsored by Biogen. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

In this study, researchers will learn how the body processes a study drug called BIIB144. This is a "first-in-human" study. This means that this study drug will be given to people for the first very time in this study. These studies are important because they help researchers learn about the safety of the study drug, how the body processes it, and what dose might be appropriate before testing it in larger groups.

The main goal of this study is to learn more about the safety of a single dose of BIIB144 compared to a placebo. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug.

The main question researchers want to answer in this study is:

How many participants have adverse events (AEs) and serious adverse events (SAEs)? An AE is a health problem that may or may not be caused by the study drug.

Researchers will also learn more about:

  • How the body processes BIIB144 compared to placebo.

This study will be done as follows:

  • Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which eligible participants will check into their study research center.
  • Participants will stay at their study research center for about 8 days. Afterwards, they will have up to 13 visits to their study research center.
  • This will be a "dose escalation" study. In this kind of study, increasing amounts of study drug are given to different groups of participants. Usually, this is done until researchers find the highest dose that does not cause harmful effects. In this study, the number of dose groups and maximum dose are planned in advance. The dose escalation will stop once these planned groups are done or if safety concerns arise.
  • There will be a total of 6 groups. In each group, participants will receive a single dose of either BIIB144 or the placebo through an intravenous (IV) needle.
  • Throughout the study, participants will give blood and urine samples. Participants will also have physical exams and answer questions about how they are feeling.
  • Each participant will be in the study for up to 44 weeks.
Read the detailed description

The primary objective of this study is to evaluate the safety and tolerability of IV administered ascending single doses of BIIB144 compared with placebo in healthy adult participants. The secondary objective is to characterize the pharmacokinetics (PK) of IV administered ascending single doses of BIIB144 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Have a (BMI) between 18 and 32 kilograms per square metre (kg/m\^2), inclusive, at Screening.
  • Must be in good health as determined by the Investigator, based on medical history and Screening evaluations.

Key Exclusion Criteria:

  • History of any cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
  • History of severe allergic or anaphylactic reactions, or of any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment.
  • History of, or ongoing, malignant disease, including solid tumors and hematologic (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 1 year prior to Day -1).
  • History of, or positive test result at Screening for, (HIV).
  • Any live or attenuated immunization or vaccination given within 14 days prior to Screening, between Screening and Day -1, or planned to be given during the study period.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    BIIB144 Cohort 1

    Participants will receive Dose A of BIIB144 or a matching placebo via intravenous (IV) infusion on Day 1.

    Drug: BIIB144 · Drug: Placebo

  • Experimental
    BIIB144 Cohort 2

    Participants will receive Dose B of BIIB144 or a matching placebo via IV infusion on Day 1.

    Drug: BIIB144 · Drug: Placebo

  • Experimental
    BIIB144 Cohort 3

    Participants will receive Dose C of BIIB144 or a matching placebo via IV infusion on Day 1.

    Drug: BIIB144 · Drug: Placebo

  • Experimental
    BIIB144 Cohort 4

    Participants will receive Dose D of BIIB144 or a matching placebo via IV infusion on Day 1.

    Drug: BIIB144 · Drug: Placebo

  • Experimental
    BIIB144 Cohort 5

    Participants will receive Dose E of BIIB144 or a matching placebo via IV infusion on Day 1.

    Drug: BIIB144 · Drug: Placebo

  • Experimental
    BIIB144 Cohort 6

    Participants will receive Dose F of BIIB144 or a matching placebo via IV infusion on Day 1.

    Drug: BIIB144 · Drug: Placebo

Interventions

  • DrugBIIB144

    Administered IV

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 280

Secondary outcomes

  1. Area Under the Serum Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC0-last) of BIIB144

    Time frame: Pre-dose and at multiple time points post-dose up to Day 280

  2. Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of BIIB144

    Time frame: Pre-dose and at multiple time points post-dose up to Day 280

  3. Maximum Observed Serum Concentration (Cmax) of BIIB144

    Time frame: Pre-dose and at multiple time points post-dose up to Day 280

  4. Time to Maximum Observed Serum Concentration (Tmax) of BIIB144

    Time frame: Pre-dose and at multiple time points post-dose up to Day 280

  5. Terminal Elimination Half-Life (t½) of BIIB144

    Time frame: Pre-dose and at multiple time points post-dose up to Day 280

  6. Total Body Clearance (CL) of BIIB144

    Time frame: Pre-dose and at multiple time points post-dose up to Day 280

  7. Volume of Distribution During the Terminal Elimination Phase (Vz) of BIIB144

    Time frame: Pre-dose and at multiple time points post-dose up to Day 280

07

Study locations

1 of 1 sites recruiting
  • Las Vegas Clinical Research Unit, PPD Development, LP
    Las Vegas, Nevada 89113, United States
    Recruiting
    • · Contact702-963-1600
    • Aishwarya Vyas Lahar · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jun 2028, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 23, 2026
StartActual
Jul 21, 2026
Primary completionEst.
Jun 19, 2028
CompletionEst.
Jun 19, 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662148
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 21, 2026
Primary completion
Jun 19, 2028 (estimated)
Completion
Jun 19, 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion